Drugs / etakafusp alfa
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07300475 | Oct 2026 → Jul 2030 expected | triple-negative breast carcinoma | Washington University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07037758 | Sep 2025 → Mar 2028 expected | small cell lung carcinoma | Amgen | Recruiting | No outcome recorded |
| Phase 1 | NCT05653882 | Jan 2023 → Aug 2026 overdue | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, renal cell carcinoma | Asher Biotherapeutics, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2026-05-21 | Asher Biotherapeutics, Inc. | Results Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline asherbio.com ↗
Updated data to be presented at ASCO continue to support the differentiated profile of AB248, with robust and selective CD8+ T-cell expansion, encouraging antitumor activity in a heavily pretreated melanoma population and a tolerability profile that supports further evaluation. |
| 2024-04-03 | Asher Biotherapeutics, Inc. | Results Asher Bio Announces Publications in Cancer Discovery Highlighting the Differentiated Profile of AB248, its CD8+ T Cell Selective IL-2 Product Candidate asherbio.com ↗
In variety of preclinical models, AB248 demonstrates improved anti-tumor activity and reduced toxicity compared to untargeted “not-α”IL-2, as well as the ability to reinvigorate dysfunctional T cells |
| 2022-11-10 | Asher Biotherapeutics, Inc. | Results Asher Bio Presents New Preclinical Data at SITC 2022 Further Supporting Advancement of AB248 and AB821 as Highly Differentiated Cis-targeted Cancer Immunotherapies asherbio.com ↗ |
| 2022-10-05 | Asher Biotherapeutics, Inc. | Results Asher Bio to Present New Preclinical Data for CD8+ T Cell Targeted Immunotherapies, AB248 and AB821, at SITC 2022 asherbio.com ↗
CD8+ T cell selectivity of AB248 is essential for optimal anti-tumor activity and safety in nonclinical models |
| 2022-04-08 | Asher Biotherapeutics, Inc. | Results Asher Bio to Present New Preclinical Data Demonstrating Differentiated Profile of AB248, its Lead Cis-targeted IL-2 Immunotherapy, at AACR Annual Meeting asherbio.com ↗
In addition, data demonstrated that AB248 augments effector cytokine production in CD8+ T cells that also receive a T cell receptor signal. |
| 2021-11-12 | Asher Biotherapeutics, Inc. | Results Asher Bio Announces New Preclinical Data Demonstrating Best-in-Class Potential of AB248, its Lead Cis-targeted IL-2 Immunotherapy asherbio.com ↗
today announced new preclinical data demonstrating proof of concept for its cis-targeting platform and lead program AB248. |
| 2021-10-01 | Asher Biotherapeutics, Inc. | Results Asher Bio to Present Preclinical Proof-of-Concept Data for AB248, a Highly Selective CD8-targeted IL-2 Therapy, at SITC 2021 asherbio.com ↗
Collectively, the presentations demonstrate preclinical proof-of-concept for Asher Bio’s cis-targeting approach and lead program AB248. |
All press releases naming this drug 12 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | etakafusp alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05653882 ↗ |
| Known as | AB248 | “Intravenous infusion of etakafusp alfa (AB248): CD8+ T cell selective interleukin-2 investigational drug” NCT05653882 ↗ |
| Modality | Protein / enzyme biologic | “CD8+ T cell selective interleukin-2 investigational drug” NCT05653882 ↗ |
| Route | Intravenous | “Intravenous infusion of etakafusp alfa (AB248)” NCT05653882 ↗ |